If you have aching knees, stiff hands, a sore back, or joints that simply do not move as easily as they used to, there is a good chance you have encountered glucosamine.
For decades, glucosamine supplements have been marketed for joint health, particularly to people with osteoarthritis. It became so commonplace that early in my practice, I used glucosamine and chondroitin with many of my own patients.
Eventually, I stopped.
At the time, my concern was not that glucosamine was dangerous. I simply was not seeing the results I expected.
Now, a newly published study examining glucosamine and Alzheimer’s disease has given me another reason to question its use.¹
Before anyone panics or throws away a bottle of supplements, however, we need to look carefully at what the research actually found, what it did not find, and what it might mean for people trying to make intelligent decisions about their joint health.
Why I Stopped Recommending Glucosamine Years Ago
Early in my practice, glucosamine and chondroitin supplements were enormously popular.
Study after study seemed to suggest they could benefit people with joint problems. As a chiropractor, I certainly had no shortage of patients experiencing joint discomfort, so I had plenty of opportunities to see how these products performed in the real world.
Over time, something bothered me.
I was not seeing much difference in the patients taking them.
I spoke with colleagues who were using glucosamine and chondroitin, and many were having similar experiences. That led me to look more closely at the research.
And the research turned out to be far less straightforward than the enthusiasm surrounding these supplements suggested.
A 2013 meta-analysis of 19 randomized, double-blind, placebo-controlled trials involving 3,159 patients illustrates the problem. Researchers found that glucosamine hydrochloride did not significantly reduce knee osteoarthritis pain. Glucosamine sulfate showed some evidence of improved function when taken for longer than six months, but it did not demonstrate a significant pain-reduction benefit over that period.²
A separate review of the literature, which evaluated seven meta-analyses, one systematic review, and five randomized clinical trials, similarly concluded that the best available evidence it examined did not demonstrate clinically relevant benefits from glucosamine and chondroitin for knee or hip osteoarthritis.³
At the same time, other systematic reviews and meta-analyses have reported some evidence of benefit, particularly for certain measures of pain and depending on the glucosamine preparation studied.⁴˒⁵
In other words, I do not think it is scientifically accurate to say that every study shows glucosamine does nothing.
The evidence is more complicated than that.
But it was uncertain enough, and my clinical experience unimpressive enough, that I stopped recommending it.
That decision ultimately led me to develop my own approach to supporting joint health.
Now there is another piece of research we need to consider.
What Researchers Found About Glucosamine and Alzheimer’s Disease
In 2026, researchers published a study in Nature Metabolism examining a biological process called glycosylation and its potential role in Alzheimer’s disease.¹
Glycosylation is a normal process in which sugar molecules are attached to proteins and other molecules. The researchers found evidence of abnormally increased glycan production, or hyperglycosylation, in Alzheimer’s disease brains.¹
Then things got particularly interesting.
In mouse models of Alzheimer’s disease, reducing the activity of certain enzymes involved in glycan production improved cognitive outcomes. Giving the mice oral glucosamine produced the opposite result: cognitive impairment became worse.¹
Researchers also examined electronic health records from people with mild cognitive impairment, or MCI, and Alzheimer’s disease and related dementias.
Among people with MCI, glucosamine use was associated with a greater likelihood of progressing to Alzheimer’s disease and related dementias. Among those who already had Alzheimer’s disease and related dementias, glucosamine use was associated with worse survival.¹
Those findings got my attention.
What This Research Means to Me
Let’s be clear about what this study does and does not tell us.
The human findings were retrospective. Researchers examined existing health records rather than randomly assigning people to take glucosamine or a placebo. The findings also involved people who already had mild cognitive impairment or Alzheimer’s disease and related dementias.¹
So no, this study does not prove that glucosamine causes Alzheimer’s disease, nor does it tell us that a cognitively healthy person taking glucosamine will develop it.
But “not proven” does not mean “not concerning.”
This study gives us several pieces of evidence worth considering together: a potential biological mechanism involving increased glycosylation, experimental evidence that glucosamine worsened cognition in an Alzheimer’s mouse model, and an association between glucosamine use and worse outcomes in people who already had cognitive impairment.¹
For me, that changes the equation.
Remember, I had already stopped recommending glucosamine years ago because I was not impressed with the results I saw in my patients. When I dug into the scientific literature, I found an evidence base that was far more mixed than glucosamine’s popularity might suggest.²˒³˒⁴˒⁵
Now there is credible research raising a new concern about potential harm.
I do not need to claim that glucosamine causes Alzheimer’s disease to take that seriously. When I already have questions about how much benefit something provides, new evidence suggesting potential harm weighs heavily in my risk-benefit calculation.
If you take glucosamine regularly, I think there is a simple question worth asking:
Is it actually helping you?
Do your joints hurt less? Are you moving more comfortably? Has your function noticeably improved?
If the answer is unclear, it may be time to reconsider why you are taking it. And if you have mild cognitive impairment or dementia, I believe these new findings are particularly important to discuss with your physician or another qualified healthcare professional.
Future clinical research will tell us more. In the meantime, informed decisions do not require panic. They require looking at both sides of the equation: What am I gaining, and what potential risks am I willing to accept?
Why I Chose a Different Approach to Joint Support
When I stopped relying on glucosamine and chondroitin, I still had the same problem in front of me.
My patients had joint discomfort, stiffness, and mobility issues, and I wanted another way to support them.
So I went back to the principles I was already using in developing my other bioformulas and created Joint Health, a glucosamine-free formula.
Joint Health uses a combination of gemmotherapy, lithotherapy, and potentized organotherapy ingredients selected according to the formulation principles I use in my practice. These include European Grape Vine buds (Vitis vinifera), Mountain Pine buds (Pinus montana), Wild Woodvine shoots (Ampelopsis weitchii), Quadratic Feldspar, and potentized Cartilage.
Rather than continue relying on glucosamine, I developed Joint Health using the formulation principles and ingredients I had come to trust in my practice.
One of the first patients to whom I recommended Joint Health was George, who was 90 years young at the time. He told me that although he “can’t do much tennis playing,” he was pain free and taking walks regularly.
Experiences like George’s are part of why I continued working with this approach in my practice.
Informed Decisions Are Better Than Fear
Health headlines have a way of turning uncertainty into certainty.
“Linked to” becomes “causes.”
“May increase risk” becomes “dangerous.”
That is not what I want you to take from this research.
The new glucosamine study does not give us the final word. But it does give us information worth taking seriously, particularly for people who already have mild cognitive impairment or Alzheimer’s disease and related dementias.¹
For adults taking glucosamine for their joints, I think there is a more productive response than fear.
Get curious.
Look at what you are taking. Ask what evidence supports it. Pay attention to whether it is actually helping you. And as new evidence emerges, be willing to reconsider the risk-benefit equation.
Something being popular or available over the counter does not automatically make it the right choice for you.
I stopped recommending glucosamine long before this latest study because I was not satisfied with the results I was seeing.
This new research gives me another reason to stand by that decision.
Looking for a Glucosamine-Free Approach to Joint Support?
If joint discomfort is affecting how comfortably you move and you are reconsidering what you take for joint support, you can learn more about Dr. Garber’s Joint Health bioformula, my glucosamine-free approach to supporting joint health.
Learn more about Joint Health →
FAQ
Does glucosamine cause Alzheimer’s?
Current evidence does not demonstrate that glucosamine causes Alzheimer’s. New research has identified an association between glucosamine use and worse outcomes among people with existing cognitive impairment, alongside experimental findings in Alzheimer’s mouse models.
Should I stop taking glucosamine?
Do not make a medical decision based solely on one study or this article. If you take glucosamine, particularly if you have mild cognitive impairment or dementia, discuss the emerging evidence with an appropriate healthcare professional.
Are there glucosamine-free options for joint support?
Yes. Joint supplements do not have to contain glucosamine. Dr. Garber developed Joint Health as a glucosamine-free approach after becoming dissatisfied with the results he observed using glucosamine and chondroitin in his practice.
References
1. Hawkinson TR, Liu Z, Ribas RA, et al. Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nature Metabolism. 2026;8(6):1410-1425. doi:10.1038/s42255-026-01538-4. PMID: 42265388.
2. Wu D, Huang Y, Gu Y, Fan W. Efficacies of different preparations of glucosamine for the treatment of osteoarthritis: a meta-analysis of randomised, double-blind, placebo-controlled trials. International Journal of Clinical Practice. 2013;67(6):585-594. doi:10.1111/ijcp.12115. PMID: 23679910.
3. Lopes Júnior OV, Inácio AM. Use of glucosamine and chondroitin to treat osteoarthritis: a review of the literature. Revista Brasileira de Ortopedia. 2013;48(4):300-306. doi:10.1016/j.rboe.2012.12.001. PMID: 31304125.
4. Simental-Mendía M, Sánchez-García A, Vilchez-Cavazos F, et al. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. Rheumatology International. 2018;38(8):1413-1428. doi:10.1007/s00296-018-4077-2. PMID: 29947998.
5. Ogata T, Ideno Y, Akai M, et al. Effects of glucosamine in patients with osteoarthritis of the knee: a systematic review and meta-analysis. Clinical Rheumatology. 2018;37(9):2479-2487. doi:10.1007/s10067-018-4106-2. PMID: 29713967.
